These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10908842)
1. Paclitaxel and carboplatin in bladder cancer: recent developments. Vaughn DJ Eur J Cancer; 2000 Jul; 36 Suppl 2():7-12. PubMed ID: 10908842 [TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Edelman MJ; Meyers FJ; Miller TR; Williams SG; Gandour-Edwards R; deVere White RW Urology; 2000 Apr; 55(4):521-5. PubMed ID: 10736495 [TBL] [Abstract][Full Text] [Related]
3. Review and outlook for the role of paclitaxel in urothelial carcinoma. Vaughn DJ Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of advanced transitional-cell carcinoma of the bladder. Miller RS; Torti FM Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma. Edelman MJ; Meyers FJ; Houston J; Lauder I Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226 [TBL] [Abstract][Full Text] [Related]
6. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851 [TBL] [Abstract][Full Text] [Related]
7. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study. Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525 [TBL] [Abstract][Full Text] [Related]
8. The role of taxanes in the management of bladder cancer. Galsky MD Oncologist; 2005; 10(10):792-8. PubMed ID: 16314289 [TBL] [Abstract][Full Text] [Related]
10. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. Boccardo F; Pace M; Guarneri D; Canobbio L; Curotto A; Martorana G Cancer; 1994 Apr; 73(7):1932-6. PubMed ID: 8137220 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel in the treatment of advanced urothelial cancer. Bajorin DF Oncology (Williston Park); 2000 Jan; 14(1):43-52, 57; discussion 58, 61-2. PubMed ID: 10680149 [TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855 [TBL] [Abstract][Full Text] [Related]
13. Novel gemcitabine-containing triplets in the management of urothelial cancer. Hussain M; Vaishampayan U; Smith DC Semin Oncol; 2002 Feb; 29(1 Suppl 3):20-4. PubMed ID: 11894004 [TBL] [Abstract][Full Text] [Related]
17. Overview of bladder cancer trials in the European Organization for Research and Treatment. de Wit R; Cancer; 2003 Apr; 97(8 Suppl):2120-6. PubMed ID: 12673705 [TBL] [Abstract][Full Text] [Related]